Semarion

Yet another fantastic ELRIG UK Drug Discovery conference! A big thank you to the organisers. We were thrilled with the interest in our SemaCyte® technology, particularly around applications like assay-ready NanoBRET transfected cells and multiplexing various cell models into a single well to supercharge high-content imaging for compound profiling or arrayed CRISPR screening. 🔥 Our booth at the Breakthrough Zone had lots of traffic, and we appreciate everyone who stopped by. We’ll be in touch soon to arrange demos and evaluation projects. 🔬 It was great to discuss and connect with our friends at BlueCatBio, Revvity, SPT Labtech, Molecular Devices, TTP plc, Axol Bioscience Ltd., Nikon Microscope Solutions Europe, Yokogawa, Innoprot, and Thermo Fisher Scientific. Other highlights: ✳️ Our CEO, Jeroen Verheyen, delivered a company flash talk. ✳️ Our biologist, Blaise Louis, presented her poster on assay-ready NanoBRET transfected cells. ✳️ Our biology lead, Daniel Weekes, shared his work on supercharging high-content imaging with cell multiplexing, including arrayed CRISPR screening using SemaCyte® microcarriers, done in collaboration with Sunil Modi at the Milner Therapeutics Institute. ✳️ Our collaborator, Simon Reidar Stockwell, from o2h discovery , presented a poster on how cell multiplexing accelerates DNA damage response assays. In case you missed us, here are some resources: 🔷 SemaCyte Brochure: https://lnkd.in/eR5QPkWE 🔷 Supercharging High Content Imaging with Cell Multiplexing: https://lnkd.in/eCMDdzqj 🔷 Assay-Ready NanoBRET Transfected Cells: https://lnkd.in/edHaKCHk ℹ️ If you’re interested in trying the SemaCyte® microcarrier platform to accelerate your workflows, feel free to reach out to Semarion: https://lnkd.in/etw4Tp3s ℹ️ For CRO multiplexed cell panel screens for compound profiling, touch base with o2h discovery : https://lnkd.in/dFQdm2z6 ℹ️ To collaborate on arrayed CRIPR screens, connect with the Milner Therapeutics Institute: https://lnkd.in/eQAUz85e See you all at the next event!

We’re at #Excel London for ELRIG UK’s #DrugDiscovery2024! The exhibitor hall is buzzing as the drug discovery community comes together for this annual event to share the latest industry innovations and breakthroughs - we’re looking forward to a busy few days of meetings 👋 We started today with the keynote: “Using the Very Small to Tackle the Very Large”, followed by five tracks covering early drug discovery to clinical translation. Be sure to catch our poster picks, which are being presented from 5 PM today: ➡️ Arrayjet: “Small Molecule Microarray (SMM) as a tool for rapid, efficient hit-identification against both protein and RNA targets” 📍 Poster Board 12 ➡️ Bio-Rad Laboratories: “Improving Flow Cytometry Data with StarBright Dyes: Fluorophores with High Stability and Assay Compatibility” 📍 Poster Board 26 “StarBright Yellow, 561 nm Excitable Dyes, Superior Alternative to PE and PE-tandems with Improved Stability and Better Spectral Properties” 📍 Poster Board 82 ➡️ Semarion: “Streamlining Transient Transfection Assays: Freezing Adherent Cells with SemaCyte® Microcarriers” 📍 Poster Board 54 “Transforming Image-Based Assays: Optical Barcoding and High-Order Multiplexing with the SemaCyte® Multiplex Platform” 📍 Poster Board 106 ➡️ Sphere Fluidics Limited: “Picodroplets for Biologics Discovery and Cell Line Development: Accelerating the Discovery Process” 📍 Poster Board 63 ➡️CN Bio : “Defining validation criteria for a primary jejunum and primary hepatocyte dual-organ MPS: a promising tool for more predictive studies of human drug ADME and oral bioavailability” 📍 Poster Board 69 ➡️ PhoreMost Ltd: “Systematic Identification of Novel Targeted Protein Degradation Mechanisms Using SITESEEKER® Technology” 📍 Poster Board 216 ➡️ ENHANC3D GENOMICS: “3D Genomics Illuminates The Dark Genome” 📍 Poster Board 263 Also, don’t miss the Learning Zone panel session at 5:00 PM on “Networking Like a Boss” for top networking tips, where Amy Prosser from Phoremost will be on the panel. For the full programme, visit: https://rb.gy/6x35ht

🚀 We are thrilled to be part of the ELRIG UK Drug Discovery conference in London on October 3-4. You can find us in the 𝗕𝗿𝗲𝗮𝗸𝘁𝗵𝗿𝗼𝘂𝗴𝗵 𝗭𝗼𝗻𝗲 at our booth, where we’ll be showcasing how our SemaCyte® Microcarrier Platform is 𝗿𝗲𝘃𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝗶𝘀𝗶𝗻𝗴 𝗮𝗱𝗵𝗲𝗿𝗲𝗻𝘁 𝗰𝗲𝗹𝗹 𝗮𝘀𝘀𝗮𝘆𝘀 and accelerating drug discovery. 🎤 Join us for a 𝗳𝗹𝗮𝘀𝗵 𝘁𝗮𝗹𝗸 𝗶𝗻 𝘁𝗵𝗲 𝗕𝗿𝗲𝗮𝗸𝘁𝗵𝗿𝗼𝘂𝗴𝗵 𝗧𝗵𝗲𝗮𝘁𝗿𝗲 on Wednesday, October 3rd, 12.45-14.00, where we’ll be diving into how SemaCyte® microcarriers can streamline cell-based assays, with real-world applications in target discovery and compound profiling. 🧬 We’re also excited that SemaCyte® Microcarriers are featured in 𝘁𝗵𝗿𝗲𝗲 𝗽𝗼𝘀𝘁𝗲𝗿𝘀 at the event: • 𝗣𝗼𝘀𝘁𝗲𝗿 𝟭𝟬𝟲: Supercharging High-Content Imaging with SemaCyte® Microcarriers (by Daniel Weekes, Semarion & Sunil Modi, Milner Therapeutics Institute) • 𝗣𝗼𝘀𝘁𝗲𝗿 𝟱𝟰: Accelerating Transient Transfection Assays with Cryopreserved Cells (by Blaise Louis, Semarion) • 𝗣𝗼𝘀𝘁𝗲𝗿 𝟵𝟯: High-Content Analysis of DNA Damage Markers in Multiplexed Cell Lines (Simon Reidar Stockwell, o2h discovery ) 🔬 Come have a chat with us at the booth to learn how SemaCyte® can 𝗯𝗼𝗼𝘀𝘁 𝘆𝗼𝘂𝗿 𝗱𝗿𝘂𝗴 𝗱𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆 𝘄𝗼𝗿𝗸𝗳𝗹𝗼𝘄𝘀 or sign up for more info here: https://lnkd.in/eAxT5iwb Looking forward to seeing you there! #drugdiscovery #biotech #cellassays #highcontentimaging #innovation #Semarion #SemaCyte #ELRIG

Excited to share insights from my recent interview with the Technology Networks on the transformative potential of Semarion's SemaCyte® platform and our journey to winning the SLAS (Society for Laboratory Automation and Screening) Ignite Award. The rapid advancements in cell-based assays and screening are revolutionizing drug discovery by enhancing speed, accuracy, and efficiency. There is a drive to investigate complexity at scale and produce more physiologically relevant data faster and earlier in the drug discovery process. At Semarion, we’re at the forefront of this transformation with our innovative SemaCyte® technology, which turns adherent cells into liquid reagents. This breakthrough drastically improves the scalability, reliability, and throughput of cell assays, accelerating data generation and reducing costs. Key highlights from the interview: 🔬 SemaCyte® Platform: Our microcarrier technology barcodes and mobalises adherent cells, enabling next gen automation and miniaturization. This streamlines workflows and supercharges high-content, high-throughput data generation. ❄️ Cryopreservation: By cryopreserving assay-ready cells, we eliminate lengthy preparation times and batch variability, making the process more efficient and reliable. 🔍 Multiplexing & Miniaturization: The platform supports multiplexing different cell types in a single well and reduces the number of cells needed, enhancing the efficiency and cost-effectiveness of drug discovery. We envision a future where advanced materials science, automation, and data analytics converge to further accelerate and refine the drug discovery process. Platforms like SemaCyte® will be pivotal in driving these changes, facilitating faster, more precise, and scalable research. A big thank you to SLAS for recognizing our efforts with the Ignite Award and to Technology Networks for the opportunity to discuss our work. Read the full interview here: https://lnkd.in/euHMBPGy To learn more about what Semarion does, visit www.semarion.com. Feel free to reach out for more information and access to our technology. #drugdiscovery #biotechnology #innovation #SLAS2024 #SemaCyte #Semarion #cellassays #biopharma #automation #datageneration

We are thrilled to announce that Semarion has won the SLAS Ignite Award for the most innovative laboratory automation start-up in Europe! 🏆 Our SemaCyte® platform, which revolutionizes in vitro drug discovery by mobilizing and barcoding adherent cells, has been recognized for its groundbreaking impact on accelerating drug development. This award underscores our commitment to transforming cell biology automation and highlights our platform's potential to drive significant advancements in the biopharma industry. Thank you to the SLAS (Society for Laboratory Automation and Screening) community and our partners for your support! If you have not come across SLAS before they are a 19,000 member strong community of people pushing the boundaries of life sciences technologies. We saw great traffic and interest from various pharma and life sciences organisations at our Booth. Certainly check out their Innovation AveNEW and Ignite programme which gives free access to emerging companies to their amazing events in the US and the EU. A big thanks to our new SLAS friends for their insightful chats and input, specially Severine Tamas-Lhoustau, Vicki Loise, Héctor Martínez, Elodie Sollier, and Zachary A. Gurard-Levin. Great to see such a quick report from European Biotechnology - Life Science and Industry Magazine (EBM). Shout-out to Zyme Communications Ltd for their amazing PR support. Credit to our fantastic Semarion team in Cambridge, UK. Our Co-Founders Jeroen Verheyen & Tarun Vemulkar represented the company in Barcelona. #Innovation #Biotech #SLASIgniteAward #DrugDiscovery #LabAutomation https://lnkd.in/gQWHvVnx

Great to see our SemaCyte Multiplexing Platform being showcased by Genetic Engineering & Biotechnology News as one of the "Products to Watch" in their May 2024 issue! They describe: "The SemaCyte® Multiplexing Platform has been launched as an expansion to the existing SemaCyte Microcarrier platform to utilize optical barcoding to accelerate screening processes during in vitro drug discovery. The platform was designed specifically to augment microplate-based high-content imaging (HCI) approaches. The company claims the SemaCyte Multiplexing Platform uses optical barcodes to tag and differentiate individual cells and cell types while preserving natural morphology, with each microcarrier capable of carrying millions of unique identifiers. Each barcode can be viewed using brightfield microscopy, and digitally deconvoluted using the company’s Semalyse software, included within the platform." Full magazine issue: https://lnkd.in/eVSik5Bx https://lnkd.in/eKU45Abx #DrugDiscovery #Innovation #Biotechnology #Research

Exciting News! Semarion Advances to the Finals of the SLAS Ignite Award! We’re thrilled to announce that Semarion has made it to the finals of the prestigious SLAS Ignite Award. As part of the Innovation AveNEW at SLAS Europe 2024 in Barcelona, we invite you to visit Booth 512B and chat with us. Discover how we’re revolutionizing adherent cell assays and shifting the paradigm. SLAS (Society for Laboratory Automation and Screening) brings together stakeholders from accross the research and tools industry to pave the way for enhanced lab automation and standardisation. 🗓️ Join Us for the Ignite Award Finalist Presentations: Date: May 28th Time: 13:30 - 14:30 Location: Exhibition Theatre Add to Conference Calendar: https://cdmcd.co/4RRjwn 🔬 Introducing SemaCyte: Transforming Adherent Cell Handling Our SemaCyte platform redefines how adherent cells are handled, stored, and assayed. These well-shaped, barcoded microcarriers mobilise and track colonies of adherent cells. Seamlessly integrating with drug discovery workflows, SemaCytes deliver a remarkable 10x increase in data throughput. 🔑 Unique Features: Storage Innovation: Store fully adherent cells inside cryovials. High-Order Cell Multiplexing: Uniquely enable advanced multiplexing. Ultra-Miniaturized Assays: Beyond current 384 and 1,536-well plates. Move Adhered Cells: Unlocking next-gen cell biology automation. 🔍 Versatile Compatibility: Our approach works seamlessly with various assay methodologies, from high-content imaging to biochemical assays. Learn more about Semarion and our SemaCyte technology at www.semarion.com. #CellAssays #DrugDiscovery #LabAutomation #SLASEurope2024

It’s wonderful to see portfolio companies thriving.   In the last week, Semarion, has made it onto Business Weekly newspaper’s Killer50 Life Sciences list! The Killer50 celebrates the brightest and most innovative life sciences companies in Cambridge.   Also, Adora Digital Health has been awarded the Rising Star Award and Health & Wellbeing StartUp of the Year for the East of England in the UK StartUp Awards.   These awards reflect Adora’s commitment to transforming women’s experience of the menopause in the workplace. Wishing the team the best of the luck in the UK finals later this year! Find out more about these two brilliant companies – links in the comments. #Innovation #Cambridge #Killer50 #StartUp #Awards #Menopause #WomensHealth #FemTech

I can officially announce my 2nd contract. 😀

Semarion. impulse Alum Jeroen Verheyen. We are super proud of how well you and Tarun Vemulkar are doing, and thank you for mentioning us in this vid as being helpful to you in your startup journey! https://lnkd.in/gu3-XKSr Thank you also IE Cambridge (Innovation & Entrepreneurship) for producing this content, and your hard work in supporting innovation in the Cambridge ecosystem. impulse is pleased to be part of the rich support network in Cambridge including the likes of CUTEC - Cambridge University Technology and Enterprise Club, Cambridge Enterprise and Milner Therapeutics Institute, also mentioned in this video. #entrepreneurship #deeptech #lifesciences #innovation Maxwell Centre, University of Cambridge University of Cambridge Yupar Myint Linh Richardson Beth Warmington